Extracellular Vesicle-Derived Protein File from Peripheral Blood Predicts Immune-Related Adverse Events in Gastric Cancer Patients Receiving Immunotherapy
Immune checkpoint inhibitors (ICIs) initiate a new stage for gastric cancer (GC) therapeutics, and plenty of patients have already benefited from ICIs. Liquid biopsy promotes the development of precision medicine of GC. However, due to the lack of precision biomarkers of immune-related adverse event...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/17/4167 |
| _version_ | 1797496082432786432 |
|---|---|
| author | Fangli Jiang Zhening Zhang Xiaoyi Chong Lin Shen Meng Fan Xuan Liu Jin An Zhi Peng Cheng Zhang |
| author_facet | Fangli Jiang Zhening Zhang Xiaoyi Chong Lin Shen Meng Fan Xuan Liu Jin An Zhi Peng Cheng Zhang |
| author_sort | Fangli Jiang |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) initiate a new stage for gastric cancer (GC) therapeutics, and plenty of patients have already benefited from ICIs. Liquid biopsy promotes the development of precision medicine of GC. However, due to the lack of precision biomarkers of immune-related adverse events (irAEs), the safety of ICIs-treated GC patients cannot be guaranteed. In our study, GC patients treated with ICIs were included for investigating the correlation between irAEs of ICIs and corresponding outcomes. We also explored the potential of biomarkers of irAEs via EV-derived proteins. Dynamic plasma was taken from 102 ICIs-treated GC patients generated retrospectively or prospectively, who were divided into discovery and validating cohorts. Plasma EV-derived protein profiles were described, and two EV-proteins, inducible T-cell co-stimulator (EV-ICOS) and indoleamine 2,3-dioxygenase 1(EV-IDO1), from 42 vital proteins were screened to predict the prognosis of ICIs with irAEs. Our work is the first to propose that EV-proteins can predict ICIs-corresponding irAEs, which can be conducive to the diagnosis and treatment of GC patients, and to facilitate the screening of beneficiaries. |
| first_indexed | 2024-03-10T01:58:35Z |
| format | Article |
| id | doaj.art-2011eeee533c4e7a8255fe48d9871c45 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T01:58:35Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-2011eeee533c4e7a8255fe48d9871c452023-11-23T12:50:58ZengMDPI AGCancers2072-66942022-08-011417416710.3390/cancers14174167Extracellular Vesicle-Derived Protein File from Peripheral Blood Predicts Immune-Related Adverse Events in Gastric Cancer Patients Receiving ImmunotherapyFangli Jiang0Zhening Zhang1Xiaoyi Chong2Lin Shen3Meng Fan4Xuan Liu5Jin An6Zhi Peng7Cheng Zhang8Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, 52 Fucheng Road, Hai-Dian District, Beijing 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, 52 Fucheng Road, Hai-Dian District, Beijing 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, 52 Fucheng Road, Hai-Dian District, Beijing 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, 52 Fucheng Road, Hai-Dian District, Beijing 100142, ChinaEVbio Technology Co., Ltd., Beijing 102200, ChinaEVbio Technology Co., Ltd., Beijing 102200, ChinaEVbio Technology Co., Ltd., Beijing 102200, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, 52 Fucheng Road, Hai-Dian District, Beijing 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, 52 Fucheng Road, Hai-Dian District, Beijing 100142, ChinaImmune checkpoint inhibitors (ICIs) initiate a new stage for gastric cancer (GC) therapeutics, and plenty of patients have already benefited from ICIs. Liquid biopsy promotes the development of precision medicine of GC. However, due to the lack of precision biomarkers of immune-related adverse events (irAEs), the safety of ICIs-treated GC patients cannot be guaranteed. In our study, GC patients treated with ICIs were included for investigating the correlation between irAEs of ICIs and corresponding outcomes. We also explored the potential of biomarkers of irAEs via EV-derived proteins. Dynamic plasma was taken from 102 ICIs-treated GC patients generated retrospectively or prospectively, who were divided into discovery and validating cohorts. Plasma EV-derived protein profiles were described, and two EV-proteins, inducible T-cell co-stimulator (EV-ICOS) and indoleamine 2,3-dioxygenase 1(EV-IDO1), from 42 vital proteins were screened to predict the prognosis of ICIs with irAEs. Our work is the first to propose that EV-proteins can predict ICIs-corresponding irAEs, which can be conducive to the diagnosis and treatment of GC patients, and to facilitate the screening of beneficiaries.https://www.mdpi.com/2072-6694/14/17/4167immune checkpoint inhibitorsimmune-related adverse eventsexosomesICOSIDO1 |
| spellingShingle | Fangli Jiang Zhening Zhang Xiaoyi Chong Lin Shen Meng Fan Xuan Liu Jin An Zhi Peng Cheng Zhang Extracellular Vesicle-Derived Protein File from Peripheral Blood Predicts Immune-Related Adverse Events in Gastric Cancer Patients Receiving Immunotherapy Cancers immune checkpoint inhibitors immune-related adverse events exosomes ICOS IDO1 |
| title | Extracellular Vesicle-Derived Protein File from Peripheral Blood Predicts Immune-Related Adverse Events in Gastric Cancer Patients Receiving Immunotherapy |
| title_full | Extracellular Vesicle-Derived Protein File from Peripheral Blood Predicts Immune-Related Adverse Events in Gastric Cancer Patients Receiving Immunotherapy |
| title_fullStr | Extracellular Vesicle-Derived Protein File from Peripheral Blood Predicts Immune-Related Adverse Events in Gastric Cancer Patients Receiving Immunotherapy |
| title_full_unstemmed | Extracellular Vesicle-Derived Protein File from Peripheral Blood Predicts Immune-Related Adverse Events in Gastric Cancer Patients Receiving Immunotherapy |
| title_short | Extracellular Vesicle-Derived Protein File from Peripheral Blood Predicts Immune-Related Adverse Events in Gastric Cancer Patients Receiving Immunotherapy |
| title_sort | extracellular vesicle derived protein file from peripheral blood predicts immune related adverse events in gastric cancer patients receiving immunotherapy |
| topic | immune checkpoint inhibitors immune-related adverse events exosomes ICOS IDO1 |
| url | https://www.mdpi.com/2072-6694/14/17/4167 |
| work_keys_str_mv | AT fanglijiang extracellularvesiclederivedproteinfilefromperipheralbloodpredictsimmunerelatedadverseeventsingastriccancerpatientsreceivingimmunotherapy AT zheningzhang extracellularvesiclederivedproteinfilefromperipheralbloodpredictsimmunerelatedadverseeventsingastriccancerpatientsreceivingimmunotherapy AT xiaoyichong extracellularvesiclederivedproteinfilefromperipheralbloodpredictsimmunerelatedadverseeventsingastriccancerpatientsreceivingimmunotherapy AT linshen extracellularvesiclederivedproteinfilefromperipheralbloodpredictsimmunerelatedadverseeventsingastriccancerpatientsreceivingimmunotherapy AT mengfan extracellularvesiclederivedproteinfilefromperipheralbloodpredictsimmunerelatedadverseeventsingastriccancerpatientsreceivingimmunotherapy AT xuanliu extracellularvesiclederivedproteinfilefromperipheralbloodpredictsimmunerelatedadverseeventsingastriccancerpatientsreceivingimmunotherapy AT jinan extracellularvesiclederivedproteinfilefromperipheralbloodpredictsimmunerelatedadverseeventsingastriccancerpatientsreceivingimmunotherapy AT zhipeng extracellularvesiclederivedproteinfilefromperipheralbloodpredictsimmunerelatedadverseeventsingastriccancerpatientsreceivingimmunotherapy AT chengzhang extracellularvesiclederivedproteinfilefromperipheralbloodpredictsimmunerelatedadverseeventsingastriccancerpatientsreceivingimmunotherapy |